Maternal serum screening for Down's syndrome, open neural tube defects and trisomy 18
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, vol.39, no.6, pp.487-490, 2001 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 39 Issue: 6
- Publication Date: 2001
- Doi Number: 10.1515/cclm.2001.080
- Journal Name: CLINICAL CHEMISTRY AND LABORATORY MEDICINE
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.487-490
- Keywords: Down's syndrome, trisomy 18, screening : maternal serum, alpha-fetoprotein, estradiol, unconjugated, human chorionic gonadotropin, HUMAN CHORIONIC-GONADOTROPIN, DIMERIC INHIBIN-A, ALPHA-FETOPROTEIN, FETAL ANEUPLOIDY, MARKERS, AGE
- Akdeniz University Affiliated: Yes
Abstract
Maternal serum screening identifies women at an increased risk of a pregnancy with Down's syndrome or trisomy 18 or an open neural tube defect. The triple test, consisting of maternal serum alpha -fetoprotein, unconjugated estriol and human chorionic gonadotropin was carried out by a chemiluminescence immunoassay method in our laboratory. The study consisted of 373 pregnant women. The gestational range for the study group was 14-22 weeks. The mean maternal age for the study group was 28.53 +/- 5.46 years (range 17.4 to 43.5 years); 9.1% of the women were considered at high risk for Down's syndrome based on the test results. In our study the detection rate for Down's syndrome by prenatal karyotyping was 66.6%. Maternal serum screening allows reduction of the number of women requiring amniocentesis without a significant decrease in the detection rate.